Diagnostics

Kardium’s landmark FDA win and a new wave of innovators signal a biotech boom, cementing British Columbia's status as a global hub for health innovation.

A new study of 100M insurance claims reveals a shocking failure: nearly 9 in 10 women in some states get no osteoporosis care after a fracture. Why?

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

Utah's Co-Diagnostics is transferring its AI-powered diagnostic platform to a Saudi JV. It's a bold move to crack a booming market and a critical test of its strategy.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

GSK and Spero Therapeutics have won FDA approval for Utebzi, the first oral carbapenem for complex UTIs, a move that could slash healthcare costs.

With $4.3M in seed funding and a roster of industry titans, Acurion is poised to commercialize its OncoGaze™ AI, aiming to make precision oncology faster.

Chronic fatigue, anxiety, and burnout are surging. A new wave of data-driven, integrative medicine claims to have the answer, moving beyond symptoms to the root cause.

With a history of beating expectations and a flurry of strategic moves, Quest Diagnostics' July 23rd earnings report is a key vital sign for the entire diagnostics sector.

New data on ersodetug reveals a calculated strategy to conquer hyperinsulinism, balancing patient hope with the harsh realities of the biotech market.

With $1.25M in new funding, Avricore Health isn't just raising capital; it's accelerating a strategic pivot to the lucrative UK market for its HealthTab platform.

Adaptive Biotechnologies' sophisticated convertible note offering isn't just about capital; it's a strategic de-risking of its finances to accelerate its fight against cancer.

A new study validates iMDx's precision diagnostic tech, setting the stage for a strategic assault on the centralized lab model for organ rejection monitoring.

A landmark court ruling forces a recall of Siemens' latest mammography tech, handing Hologic a major victory and sending shockwaves through Europe's MedTech.

As a rare Ebola strain rages in a DRC warzone, the G7 pledges massive aid. But with fragile peace deals and no proven cure, is it enough to stop a global crisis?

A forgotten corner of oncology is set for a 14.2% CAGR. A new wave of drugs for chemo-induced neuropathy signals a major market realignment.

The PD-L1 biomarker testing market is set to double by 2036, fueling a revolution in cancer care. But as innovation races ahead, who gets left behind?

Ice Cube's BIG3 league and the PCF are deploying a new playbook, using basketball's cultural power to bring life-saving cancer screenings directly to Black men.